Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Management
Alembic Pharmaceuticals designated Mr. Amit Nayak as Senior Management Personnel effective May 1, 2026. He brings 12 years of experience in commercial excellence from pharma and consulting firms.
May 01 2026 10:05:00
Alembic Pharmaceuticals Ltd - 533573 - Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 - Incorporation Of Subsidiary Company
Alembic Pharmaceuticals Limited incorporated Alembic Lifesciences Philippines Inc. in the Philippines. This new subsidiary, with a share capital of Philippine Pesos 12 million, will focus on promoting and distributing pharmaceutical products in the region.
Apr 22 2026 19:04:00
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals received USFDA final approval for Methotrexate Injection USP, 50 mg/2 mL and 1g/40 mL single-dose vials. This approval for the oncology drug enhances the company's US product offerings, adding to its 236 cumulative ANDA approvals.
Apr 16 2026 11:04:00
Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited received USFDA final approval for Dapagliflozin Tablets, 5 mg and 10 mg. This approval makes the company eligible for 180 days of shared generic drug exclusivity in a market estimated at US$ 10,487 million.
Apr 07 2026 12:04:00
Read More